Contact Me
My Company Triple W

Role(s) in Healthcare Innovation:

Healthcare Innovator Medical Device Industry Pro

Taichi Takayanagi, MBA

About Me

Ty Takayanagi, VP of Business Development and Marketing for Triple W, San Diego, has an extensive background in the consumer tech and health device industries. Triple W is an innovator of connected health devices and developer of DFree®, the first health wearable device for urinary incontinence. Prior to Triple W, Takayanagi headed product marketing for industry leader, Sony, including the tablet, home audio and home theater, and handheld computer divisions. His Sony background, coupled with his personal experience with the challenges of caregiving, helped him to launch DFree to the U.S. market. He wants to help others who may be managing incontinence themselves or as caregivers to a loved one. Takayanagi graduated from the University of California, San Diego, with a B.A. in Economics. He also received an M.B.A. in Marketing from the University of Chicago Booth School in Business.

I am looking for healthcare innovations:

You have not backed any projects. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.